Mechanisms of prion toxicity and their relationship to prion infectivity

Neurodegeneration and Prion Disease

Volumn , Issue , 2005, Pages 217-240

  Vella, Laura ^a   Hill, Andrew F ^a   Cappai, Roberto ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900194003     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-23923-5_9     Document Type: Chapter

References (130)

1. S. B. Prusiner, Novel proteinaceous infectious particles cause scrapie. Science 216, 136-44 (1982).
2. H. Bueler, A. Aguzzi, A. Sailer, R. A. Greiner, P. Autenried, M. Aguet and C. Weissmann, Mice devoid of PrP are resistant to scrapie. Cell 73, 1339-47 (1993).
3. S. Brandner, S. Isenmann, A. Raeber, M. Fischer, A. Sailer, Y. Kobayashi, S. Marino, C. Weissmann and A. Aguzzi, Normal host prion protein necessary for scrapieinduced neurotoxicity. Nature 379, 339-43 (1996).
4. D. R. Borchelt, M. Scott, A. Taraboulos, N. Stahl and S. B. Prusiner, Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J Cell Biol 110, 743-52 (1990).
5. D. A. Kocisko, J. H. Come, S. A. Priola, B. Chesebro, G. J. Raymond, P. T. Lansbury and B. Caughey, Cell-free formation of protease-resistant prion protein. Nature 370, 471-4 (1994).
6. S. K. DebBurman, G. J. Raymond, B. Caughey and S. Lindquist, Chaperonesupervised conversion of prion protein to its protease-resistant form. Proc Natl Acad Sci USA 94, 13938-43 (1997).
7. J. Chabry, S. A. Priola, K. Wehrly, J. Nishio, J. Hope and B. Chesebro, Speciesindependent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J Virol 73, 6245-50 (1999).
8. A. F. Hill, M. Antoniou and J. Collinge, Protease-resistant prion protein produced in vitro lacks detectable infectivity. J Gen Virol 80(Pt 1), 11-4 (1999).
9. C. L. Masters, G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald and K. Beyreuther, Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82, 4245-9 (1985).
10. B. A. Yankner, L. R. Dawes, S. Fisher, L. Villa-Komaroff, M. L. Oster-Granite and R. L. Neve, Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245, 417-20 (1989).
11. R. L. Neve, L. R. Dawes, B. A. Yankner, L. I. Benowitz, W. Rodriguez and G. A. Higgins, Genetics and biology of the Alzheimer amyloid precursor. Prog Brain Res 86, 257-67 (1990).
12. G. Forloni, N. Angeretti, R. Chiesa, E. Monzani, M. Salmona, O. Bugiani and F. Tagliavini, Neurotoxicity of a prion protein fragment. Nature 362, 543-6 (1993).
13. D. R. Brown, J. Herms and H. A. Kretzschmar, Mouse cortical cells lacking cellular PrP survive in culture with a neurotoxic PrP fragment. Neuroreport 5, 2057-60 (1994).
14. S. B. Prusiner, Prions. Proc Natl Acad Sci USA 95, 13363-83 (1998).
15. H. Budka, A. Aguzzi, P. Brown, J. M. Brucher, O. Bugiani, F. Gullotta, M. Haltia, J. J. Hauw, J. W. Ironside, K. Jellinger and et al., Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol 5, 459-66 (1995).
16. C. Selvaggini, L. De Gioia, L. Cantu, E. Ghibaudi, L. Diomede, F. Passerini, G. Forloni, O. Bugiani, F. Tagliavini and M. Salmona, Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. Biochem Biophys Res Commun 194, 1380-6 (1993).
17. L. De Gioia, C. Selvaggini, E. Ghibaudi, L. Diomede, O. Bugiani, G. Forloni, F. Tagliavini and M. Salmona, Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. J Biol Chem 269, 7859-62 (1994).
18. M. F. Jobling, L. R. Stewart, A. R. White, C. McLean, A. Friedhuber, F. Maher, K. Beyreuther, C. L. Masters, C. J. Barrow, S. J. Collins and R. Cappai, The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106-126. J Neurochem 73, 1557-65 (1999).
19. M. Salmona, P. Malesani, L. De Gioia, S. Gorla, M. Bruschi, A. Molinari, F. Della Vedova, B. Pedrotti, M. A. Marrari, T. Awan, O. Bugiani, G. Forloni and F. Tagliavini, Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126. Biochem J 342(Pt 1), 207-14 (1999).
20. M. Bucciantini, E. Giannoni, F. Chiti, F. Baroni, L. Formigli, J. Zurdo, N. Taddei, G. Ramponi, C. M. Dobson and M. Stefani, Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-11 (2002).
21. A. Corsaro, S. Thellung, V. Villa, D. R. Principe, D. Paludi, S. Arena, E. Millo, D. Schettini, G. Damonte, A. Aceto, G. Schettini and T. Florio, Prion protein fragment 106-126 induces a p38 MAP kinase-dependent apoptosis in SH-SY5Y neuroblastoma cells independently from the amyloid fibril formation. Ann NY Acad Sci 1010, 610-22 (2003).
22. D. R. Brown, M. Pitschke, D. Riesner and H. A. Kretzschmar, Cellular effects of a neurotoxic prion protein are related to its β-sheet content. Neurosci. Res. Comm. 23, 119-128 (1998).
23. T. Oda, P. Wals, H. H. Osterburg, S. A. Johnson, G. M. Pasinetti, T. E. Morgan, I. Rozovsky, W. B. Stine, S. W. Snyder, T. F. Holzman and et al., Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol 136, 22-31 (1995).
24. M. P. Lambert, A. K. Barlow, B. A. Chromy, C. Edwards, R. Freed, M. Liosatos, T. E. Morgan, I. Rozovsky, B. Trommer, K. L. Viola, P. Wals, C. Zhang, C. E. Finch, G. A. Krafft and W. L. Klein, Diffusible, nonfibrillar ligands derived from Abeta 1-42 are potent central nervous system neurotoxins. PNAS 95, 6448-6453 (1998).
25. D. R. Brown, Prion protein-overexpressing cells show altered response to a neurotoxic prion protein peptide. J Neurosci Res 54, 331-40 (1998).
26. D. R. Brown, A. Besinger, J. W. Herms and H. A. Kretzschmar, Microglial expression of the prion protein. Neuroreport 9, 1425-9 (1998).
27. D. R. Brown, B. Schmidt and H. A. Kretzschmar, A prion protein fragment primes type 1 astrocytes to proliferation signals from microglia. Neurobiol Dis 4, 410-22 (1998).
28. A. Giese, D. R. Brown, M. H. Groschup, C. Feldmann, I. Haist and H. A. Kretzschmar, Role of microglia in neuronal cell death in prion disease. Brain Pathol 8, 449-57 (1998).
29. R. N. Kalaria, Microglia and Alzheimer's disease. Curr Opin Hematol 6, 15-24 (1999).
30. S. Itagaki, P. L. McGeer, H. Akiyama, S. Zhu and D. Selkoe, Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 24, 173-82 (1989).
31. A. Williams, P. J. Lucassen, D. Ritchie and M. Bruce, PrP deposition, microglial activation, and neuronal apoptosis in murine scrapie. Exp Neurol 144, 433-8 (1997).
32. P. J. Lucassen, A. Williams, W. C. Chung and H. Fraser, Detection of apoptosis in murine scrapie. Neurosci Lett 198, 185-8 (1995).
33. A. E. Williams, L. J. Lawson, V. H. Perry and H. Fraser, Characterization of the microglial response in murine scrapie. Neuropathol Appl Neurobiol 20, 47-55 (1994).
34. D. C. Guiroy, I. Wakayama, P. P. Liberski and D. C. Gajdusek, Relationship of microglia and scrapie amyloid-immunoreactive plaques in kuru, Creutzfeldt-Jakob disease and Gerstmann-Straussler syndrome. Acta Neuropathol (Berl) 87, 526-30 (1994).
35. J. W. Ironside, L. McCardle, P. A. Hayward and J. E. Bell, Ubiquitin immunocytochemistry in human spongiform encephalopathies. Neuropathol Appl Neurobiol 19, 134-40 (1993).
36. M. Miyazono, T. Iwaki, T. Kitamoto, Y. Kaneko, K. Doh-ura and J. Tateishi, A comparative immunohistochemical study of Kuru and senile plaques with a special reference to glial reactions at various stages of amyloid plaque formation. Am J Pathol 139, 589-98 (1991).
37. S. Betmouni, V. H. Perry and J. L. Gordon, Evidence for an early inflammatory response in the central nervous system of mice with scrapie. Neuroscience 74, 1-5 (1996).
38. J. M. Peyrin, C. I. Lasmezas, S. Haik, F. Tagliavini, M. Salmona, A. Williams, D. Richie, J. P. Deslys and D. Dormont, Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines. Neuroreport 10, 723-9 (1999).
39. V. Silei, C. Fabrizi, G. Venturini, M. Salmona, O. Bugiani, F. Tagliavini and G. M. Lauro, Activation of microglial cells by PrP and beta-amyloid fragments raises intracellular calcium through L-type voltage sensitive calcium channels. Brain Res 818, 168-70 (1999).
40. D. R. Brown and H. A. Kretzschmar, Microglia and prion disease: a review. Histol Histopathol 12, 883-92 (1997).
41. D. Lorton, J. M. Kocsis, L. King, K. Madden and K. R. Brunden, beta-Amyloid induces increased release of interleukin-1 beta from lipopolysaccharide-activated human monocytes. J Neuroimmunol 67, 21-9 (1996).
42. S. L. Yates, L. H. Burgess, J. Kocsis-Angle, J. M. Antal, M. D. Dority, P. B. Embury, A. M. Piotrkowski and K. R. Brunden, Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia. J Neurochem 74, 1017-25 (2000).
43. C. K. Combs, D. E. Johnson, S. B. Cannady, T. M. Lehman and G. E. Landreth, Identification of microglial signal transduction pathways mediating a neurotoxic responseto amyloidogenic fragments ofbeta-amyloid and prion proteins. J Neurosci 19, 928-39 (1999).
44. J. A. Hamilton, G. Whitty, A. R. White, M. F. Jobling, A. Thompson, C. J. Barrow, R. Cappai, K. Beyreuther and C. L. Masters, Alzheimer's disease amyloid beta and prion protein amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced proliferative response to CSF-1 (M-CSF). Brain Res 940, 49-54 (2002).
45. K. Jendroska, F. P. Heinzel, M. Torchia, L. Stowring, H. A. Kretzschmar, A. Kon, A. Stern, S. B. Prusiner and S. J. DeArmond, Proteinase-resistant prion protein accumulation in Syrian hamster brain correlates with regional pathology and scrapie infectivity. Neurology 41, 1482-90 (1991).
46. S. J. DeArmond, S. L. Yang, A. Lee, R. Bowler, A. Taraboulos, D. Groth and S. B. Prusiner, Three scrapie prion isolates exhibit different accumulation patterns of the prion protein scrapie isoform. Proc Natl Acad Sci USA 90, 6449-53 (1993).
47. H. McLennan and H. V. Wheal, The interaction of glutamic and aspartic acids with excitatory amino acid receptors in the mammalian central nervous system. Can J Physiol Pharmacol 54, 70-2 (1976).
48. G. Garthwaite, G. D. Williams and J. Garthwaite, Glutamate Toxicity: An Experimental and Theoretical Analysis. Eur J Neurosci 4, 353-360 (1992).
49. D. R. Brown, J. W. Herms, B. Schmidt and H. A. Kretzschmar, PrP and beta-amyloid fragments activate different neurotoxic mechanisms in cultured mouse cells. Eur J Neurosci 9, 1162-9 (1997).
50. W. E. Muller, H. Ushijima, H. C. Schroder, J. M. Forrest, W. F. Schatton, P. G. Rytik and M. Heffner-Lauc, Cytoprotective effect of NMDA receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell cultures. Eur J Pharmacol 246, 261-7 (1993).
51. S. Perovic, G. Pergande, H. Ushijima, M. Kelve, J. Forrest and W. E. Muller, Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Neurodegeneration 4, 369-74 (1995).
52. H. C. Schroder, S. Perovic, V. Kavsan, H. Ushijima and W. E. Muller, Mechanisms of prionSc- and HIV-1 gp120 induced neuronal cell death. Neurotoxicology 19, 683-8 (1998).
53. B. Miller, M. Sarantis, S. F. Traynelis and D. Attwell, Potentiation of NMDA receptor currents by arachidonic acid. Nature 355, 722-5 (1992).
54. B. Barbour, M. Szatkowski, N. Ingledew and D. Attwell, Arachidonic acid induces a prolonged inhibition of glutamate uptake into glial cells. Nature 342, 918-20 (1989).
55. A. Dumuis, M. Sebben, L. Haynes, J. P. Pin and J. Bockaert, NMDA receptors activate the arachidonic acid cascade system in striatal neurons. Nature 336, 68-70 (1988).
56. L. R. Stewart, A. R. White, M. F. Jobling, B. E. Needham, F. Maher, J. Thyer, K. Beyreuther, C. L. Masters, S. J. Collins and R. Cappai, Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126. J Neurosci Res 65, 565-72 (2001).
57. C. Korth, B. C. May, F. E. Cohen and S. B. Prusiner, Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 98, 9836-41 (2001).
58. A. Barret, F. Tagliavini, G. Forloni, C. Bate, M. Salmona, L. Colombo, A. De Luigi, L. Limido, S. Suardi, G. Rossi, F. Auvre, K. T. Adjou, N. Sales, A. Williams, C. Lasmezas and J. P. Deslys, Evaluation of quinacrine treatment for prion diseases. J Virol 77, 8462-9 (2003).
59. M. Daniels, G. M. Cereghetti and D. R. Brown, Toxicity of novel C-terminal prion protein fragments and peptides harbouring disease-related C-terminal mutations. Eur J Biochem 268, 6155-64 (2001).
60. F. B. Hafiz and D. R. Brown, A model for the mechanism of astrogliosis in prion disease. Mol Cell Neurosci 16, 221-32 (2000).
61. D. R. Brown, Prion protein peptide neurotoxicity can be mediated by astrocytes. J Neurochem 73, 1105-13 (1999).
62. E. T. Dayton and E. O. Major, Recombinant human interleukin 1 beta induces production of prostaglandins in primary human fetal astrocytes and immortalized human fetal astrocyte cultures. J Neuroimmunol 71, 11-8 (1996).
63. N. Stella, A. Estelles, J. Siciliano, M. Tence, S. Desagher, D. Piomelli, J. Glowinski and J. Premont, Interleukin-1 enhances the ATP-evoked release of arachidonic acid from mouse astrocytes. J Neurosci 17, 2939-46 (1997).
64. M. Moser, R. J. Colello, U. Pott and B. Oesch, Developmental expression of the prion protein gene in glial cells. Neuron 14, 509-17 (1995).
65. A. J. Raeber, R. E. Race, S. Brandner, S. A. Priola, A. Sailer, R. A. Bessen, L. Mucke, J. Manson, A. Aguzzi, M. B. Oldstone, C. Weissmann and B. Chesebro, Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J 16, 6057-65 (1997).
66. J. Sassoon, M. Daniels and D. R. Brown, Astrocytic regulation of NMDA receptor subunit composition modulates the toxicity of prion peptide PrP106-126. Mol Cell Neurosci 25, 181-91 (2004).
67. D. R. Brown and C. M. Mohn, Astrocytic glutamate uptake and prion protein expression. Glia 25, 282-92 (1999).
68. N. Vassallo and J. Herms, Cellular prion protein function in copper homeostasis and redox signalling at the synapse. J Neurochem 86, 538-44 (2003).
69. D. R. Brown, K. Qin, J. W. Herms, A. Madlung, J. Manson, R. Strome, P. E. Fraser, T. Kruck, A. von Bohlen, W. Schulz-Schaeffer, A. Giese, D. Westaway and H. Kretzschmar, The cellular prion protein binds copper in vivo. Nature 390, 684-7 (1997).
70. J. Stockel, J. Safar, A. C. Wallace, F. E. Cohen and S. B. Prusiner, Prion protein selectively binds copper (II) ions. Biochemistry 37, 7185-93 (1998).
71. M. P. Hornshaw, J. R. McDermott, J. M. Candy and J. H. Lakey, Copper bindingtothe N-terminal tandem repeat region of mammalian and avian prion protein: structural studies using synthetic peptides. Biochem Biophys Res Commun 214, 993-9 (1995).
72. D. R. Brown, F. Hafiz, L. L. Glasssmith, B. S. Wong, I. M. Jones, C. Clive and S. J. Haswell, Consequences of manganese replacement of copper for prion protein function and proteinase resistance. EMBO J 19, 1180-6 (2000).
73. B. S. Wong, D. R. Brown, T. Pan, M. Whiteman, T. Liu, X. Bu, R. Li, P. Gambetti, J. Olesik, R. Rubenstein and M. S. Sy, Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. J Neurochem 79, 689-98 (2001).
74. A. M. Thackray, R. Knight, S. J. Haswell, R. Bujdoso and D. R. Brown, Metal imbalance and compromised antioxidant function are early changes in prion disease. Biochem J 362, 253-8 (2002).
75. H. A. Kretzschmar, L. E. Stowring, D. Westaway, W. H. Stubblebine, S. B. Prusiner and S. J. Dearmond, Molecular cloning of a human prion protein cDNA. DNA 5, 315-24 (1986).
76. J. M. Gabriel, B. Oesch, H. Kretzschmar, M. Scott and S. B. Prusiner, Molecular cloning of a candidate chicken prion protein. Proc Natl Acad Sci USA 89, 9097-101 (1992).
77. B. Belosi, E. Gaggelli, R. Guerrini, H. Kozlowski, M. Luczkowski, F. M. Mancini, M. Remelli, D. Valensin and G. Valensin, Copper binding to the neurotoxic peptide PrP106-126: thermodynamic and structural studies. Chembiochem 5, 349-59 (2004).
78. E. Wong, A. M. Thackray and R. Bujdoso, Copper induces increased beta-sheet content in the scrapie-susceptible ovine prion protein PrPVRQ compared with the resistant allelic variant PrPARR. Biochem J 380, 273-82 (2004).
79. T. Miura, A. Hori-i and H. Takeuchi, Metal-dependent alpha-helix formation promoted by the glycine-rich octapeptide region of prion protein. FEBS Lett 396, 248-52 (1996).
80. M. F. Jobling, X. Huang, L. R. Stewart, K. J. Barnham, C. Curtain, I. Volitakis, M. Perugini, A. R. White, R. A. Cherny, C. L. Masters, C. J. Barrow, S. J. Collins, A. I. Bush and R. Cappai, Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126. Biochemistry 40, 8073-84 (2001).
81. D. R. Brown and A. Besinger, Prion protein expression and superoxide dismutase activity. Biochem J 334(Pt 2), 423-9 (1998).
82. F. Klamt, F. Dal-Pizzol, M. J. Conte da Frota, R. Walz, M. E. Andrades, E. G. da Silva, R. R. Brentani, I. Izquierdo and J. C. Fonseca Moreira, Imbalance of antioxidant defense in mice lacking cellular prion protein. Free Radic Biol Med 30, 1137-44 (2001).
83. D. R. Brown, R. S. Nicholas and L. Canevari, Lack of prion protein expression results in a neuronal phenotype sensitive to stress. J Neurosci Res 67, 211-24 (2002).
84. D. R. Brown and J. Sassoon, Copper-dependent functions for the prion protein. Mol Biotechnol 22, 165-78 (2002).
85. P. C. Pauly and D. A. Harris, Copper stimulates endocytosis of the prion protein. J Biol Chem 273, 33107-10 (1998).
86. W. Rachidi, A. Mange, A. Senator, P. Guiraud, J. Riondel, M. Benboubetra, A. Favier and S. Lehmann, Prion infection impairs copper binding of cultured cells. J Biol Chem 278, 14595-8 (2003).
87. D. R. Brown, Role of the prion protein in copper turnover in astrocytes. Neurobiol Dis 15, 534-43 (2004).
88. J. Collinge, M. A. Whittington, K. C. Sidle, C. J. Smith, M. S. Palmer, A. R. Clarke and J. G. Jefferys, Prion protein is necessary for normal synaptic function. Nature 370, 295-7 (1994).
89. M. A. Whittington, K. C. Sidle, I. Gowland, J. Meads, A. F. Hill, M. S. Palmer, J. G. Jefferys and J. Collinge, Rescue of neurophysiological phenotype seen in PrP null mice by transgene encoding human prion protein. Nat Genet 9, 197-201 (1995).
90. S. B. Colling, J. Collinge and J. G. Jefferys, Hippocampal slices from prion protein null mice: disrupted Ca (2+)-activated K+ currents. Neurosci Lett 209, 49-52 (1996).
91. G. R. Mallucci, S. Ratte, E. A. Asante, J. Linehan, I. Gowland, J. G. Jefferys and J. Collinge, Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J 21, 202-10 (2002).
92. K. Kristensson, B. Feuerstein, A. Taraboulos, W. C. Hyun, S. B. Prusiner and S. J. DeArmond, Scrapie prions alter receptor-mediated calcium responses in cultured cells. Neurology 43, 2335-2341 (1993).
93. K. Wong, Y. Qiu, W. Hyun, R. Nixon, J. Van Cleff, J. Sanchez-Salazar, S. B. Prusiner and S. J. DeArmond, Decreased receptor-mediated calcium response in prion-infected cells correlates with decreased membrane fluidity and IP3 release. Neurology 47, 741-750 (1996).
94. A. R. Johnston, J. R. Fraser, M. Jeffrey and N. MacLeod, Synaptic plasticity in the CA1 area of the hippocampus of scrapie-infected mice. Neurobiol Dis 5, 188-95 (1998).
95. P. A. Barrow, C. D. Holmgren, A. J. Tapper and J. G. Jefferys, Intrinsic physiological and morphological properties of principal cells of the hippocampus and neocortex in hamsters infected with scrapie. Neurobiol Dis 6, 406-23 (1999).
96. T. Florio, S. Thellung, C. Amico, M. Robello, M. Salmona, O. Bugiani, F. Tagliavini, G. Forloni and G. Schettini, Prion protein fragment 106-126 induces apoptotic cell death and impairment of L-type voltage-sensitive calcium channel activity in the GH3 cell line. J Neurosci Res 54, 341-52 (1998).
97. T. Florio, M. Grimaldi, A. Scorziello, M. Salmona, O. Bugiani, F. Tagliavini, G. Forloni and G. Schettini, Intracellular calcium rise through L-type calcium channels, as molecular mechanism for prion protein fragment 106-126-induced astroglial proliferation. Biochem Biophys Res Commun 228, 397-405 (1996).
98. S. Thellung, T. Florio, V. Villa, A. Corsaro, S. Arena, C. Amico, M. Robello, M. Salmona, G. Forloni, O. Bugiani, F. Tagliavini and G. Schettini, Apoptotic cell death and impairment of L-type voltage-sensitive calcium channel activity in rat cerebellar granule cells treated with the prion protein fragment 106-126. Neurobiol Dis 7, 299-309 (2000).
99. A. Thompson, A. R. White, C. McLean, C. L. Masters, R. Cappai and C. J. Barrow, Amyloidogenicity and neurotoxicity of peptides corresponding to the helical regions of PrP (C). J Neurosci Res 62, 293-301 (2000).
100. G. Forloni, N. Angeretti, P. Malesani, E. Peressini, T. Rodriguez Martin, P. Della Torre and M. Salmona, Influence of mutations associated with familial prion-related encephalopathies on biological activity of prion protein peptides. Ann Neurol 45, 489-94 (1999).
101. J. Nguyen, M. A. Baldwin, F. E. Cohen and S. B. Prusiner, Prion protein peptides induce alpha-helix to beta-sheet conformational transitions. Biochemistry 34, 4186-92 (1995).
102. H. Zhang, K. Kaneko, J. T. Nguyen, T. L. Livshits, M. A. Baldwin, F. E. Cohen, T. L. James and S. B. Prusiner, Conformational transitions in peptides containing two putative alpha-helices of the prion protein. J Mol Biol 250, 514-26 (1995).
103. F. Tagliavini, F. Prelli, L. Verga, G. Giaccone, R. Sarma, P. Gorevic, B. Ghetti, F. Passerini, E. Ghibaudi, G. Forloni and et al., Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro. Proc Natl Acad Sci USA 90, 9678-82 (1993).
104. M. Fischer, T. Rulicke, A. Raeber, A. Sailer, M. Moser, B. Oesch, S. Brandner, A. Aguzzi and C. Weissmann, Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J 15, 1255-64 (1996).
105. E. Flechsig, D. Shmerling, I. Hegyi, A. J. Raeber, M. Fischer, A. Cozzio, C. von Mering, A. Aguzzi and C. Weissmann, Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. Neuron 27, 399-408 (2000).
106. D. Shmerling, I. Hegyi, M. Fischer, T. Blattler, S. Brandner, J. Gotz, T. Rulicke, E. Flechsig, A. Cozzio, C. von Mering, C. Hangartner, A. Aguzzi and C. Weissmann, Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 93, 203-14 (1998).
107. S. Supattapone, P. Bosque, T. Muramoto, H. Wille, C. Aagaard, D. Peretz, H. O. Nguyen, C. Heinrich, M. Torchia, J. Safar, F. E. Cohen, S. J. DeArmond, S. B. Prusiner and M. Scott, Prion protein of 106 residues creates an artifical transmission barrier for prion replication in transgenic mice. Cell 96, 869-78 (1999).
108. V. Bonetto, T. Massignan, R. Chiesa, M. Morbin, G. Mazzoleni, L. Diomede, N. Angeretti, L. Colombo, G. Forloni, F. Tagliavini and M. Salmona, Synthetic miniprion PrP106. J Biol Chem 277, 31327-34 (2002).
109. R. H. Kimberlin and C. A. Walker, Pathogenesis of scrapie: agent multiplication in brain at the first and second passage of hamster scrapie in mice. J Gen Virol 42, 107-17 (1979).
110. A. G. Dickinson, H. Fraser and G. W. Outram, Scrapie incubation time can exceed natural lifespan. Nature 256, 732-3 (1975).
111. A. F. Hill, S. Joiner, J. Linehan, M. Desbruslais, P. L. Lantos and J. Collinge, Speciesbarrier-independent prion replication in apparently resistant species. Proc Natl Acad Sci USA 97, 10248-53 (2000).
112. R. Race and B. Chesebro, Scrapie infectivity found in resistant species. Nature 392, 770 (1998).
113. R. H. Kimberlin, C. A. Walker and H. Fraser, The genomic identity of different strains of mouse scrapie is expressed in hamsters and preserved on reisolation in mice. J Gen Virol 70(Pt 8), 2017-25 (1989).
114. R. Race, A. Raines, G. J. Raymond, B. Caughey and B. Chesebro, Long-Term Subclinical Carrier State Precedes Scrapie Replication and Adaptation in a Resistant Species: Analogies to Bovine SpongiformEncephalopathy and Variant Creutzfeldt-Jakob Disease in Humans. J. Virol. 75, 10106-10112 (2001).
115. R. Frigg, M. A. Klein, I. Hegyi, R. M. Zinkernagel and A. Aguzzi, Scrapie pathogenesis in subclinically infected B-cell-deficient mice. J Virol 73, 9584-8 (1999).
116. A. M. Thackray, M. A. Klein, A. Aguzzi and R. Bujdoso, Chronic Subclinical Prion Disease Induced by Low-Dose Inoculum. J. Virol. 76, 2510-2517 (2002).
117. A. M. Thackray, M. A. Klein and R. Bujdoso, Subclinical Prion Disease Induced by Oral Inoculation. J. Virol. 77, 7991-7998 (2003).
118. H. Bueler, A. Raeber, A. Sailer, M. Fischer, A. Aguzzi and C. Weissmann, High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol Med 1, 19-30 (1994).
119. S. J. DeArmond, W. C. Mobley, D. L. DeMott, R. A. Barry, J. H. Beckstead and S. B. Prusiner, Changes in the localization of brain prion proteins during scrapie infection. Neurology 37, 1271-80 (1987).
120. R. Gabizon, M. P. McKinley, D. Groth and S. B. Prusiner, Immunoaffinity purification and neutralizationof scrapie prion infectivity. Proc Natl Acad Sci USA 85, 6617-21 (1988).
121. R. Medori, P. Montagna, H. J. Tritschler, A. LeBlanc, P. Cortelli, P. Tinuper, E. Lugaresi and P. Gambetti, Fatal familial insomnia: a second kindred with mutation of prion protein gene at codon 178. Neurology 42, 669-70 (1992).
122. J. Collinge, F. Owen, M. Poulter, M. Leach, T. J. Crow, M. N. Rossor, J. Hardy, M. J. Mullan, I. Janota and P. L. Lantos, Prion dementia without characteristic pathology. Lancet 336, 7-9 (1990).
123. J. Collinge, M. S. Palmer, K. C. Sidle, I. Gowland, R. Medori, J. Ironside and P. Lantos, Transmission of fatal familial insomnia to laboratory animals. Lancet 346, 569-70 (1995).
124. A. F. Hill and J. Collinge, Subclinical prion infection. Trends in Microbiology 11, 578-584 (2003).
125. C. I. Lasmezas, J. P. Deslys, O. Robain, A. Jaegly, V. Beringue, J. M. Peyrin, J. G. Fournier, J. J. Hauw, J. Rossier and D. Dormont, Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 275, 402-5 (1997).
126. A. Arjona, L. Simarro, F. Islinger, N. Nishida and L. Manuelidis, Two Creutzfeldt-Jakob disease agents reproduce prion protein-independent identities in cell cultures. Proc Natl Acad Sci U S A 101, 8768-73 (2004).
127. H. Bueler, M. Fischer, Y. Lang, H. Bluethmann, H. P. Lipp, S. J. DeArmond, S. B. Prusiner, M. Aguet and C. Weissmann, Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356, 577-82 (1992).
128. R. S. Hegde, J. A. Mastrianni, M. R. Scott, K. A. DeFea, P. Tremblay, M. Torchia, S. J. DeArmond, S. B. Prusiner and V. R. Lingappa, A transmembrane form of the prion protein in neurodegenerative disease. Science 279, 827-34 (1998).
129. R. S. Hegde, P. Tremblay, D. Groth, S. J. DeArmond, S. B. Prusiner and V. R. Lingappa, Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 402, 822-6 (1999).
130. I. Sponne, A. Fifre, V. Koziel, B. Kriem, T. Oster, J. L. Olivier and T. Pillot, Oligodendrocytes are susceptible to apoptotic cell death induced by prion protein-derived peptides. Glia 47, 1-8 (2004).